Addressing the #1 Cause of Death After a Heart Attack

We’re Reinventing the Standard of Care in Mechanical Circulatory Support

THE PROBLEM

A serious, life-threatening condition - Cardiogenic Shock

Cardiogenic shock has 40%-60% mortality rate

  • #1 cause of death after a heart attack
  • Key risk for patients with Acute Decompensated Heart Failure

There remains a significant unmet clinical need

Mechanical circulatory support (MCS) is required when the heart is unable to pump sufficient blood & oxygen to the body, resulting in end-organ failure

Significant complication risks with the current standard of care

  • Major bleeding
  • Sepsis
  • Infection
  • Vascular injury
  • Hemolysis
  • Arterial blockages leading to limb ischemia or stroke

OUR SOLUTION

Introducing Percutaneous Synchronized Cardiac Assist (PSCA)

Our implant uses an inflatable balloon to apply ECG-synchronized left ventricular compression, without entering the heart or bloodstream

Enlarge photo

How it works

Less Invasive

Uses minimally invasive subxiphoid access for extravascular/extracardiac device implant

Novel Anchoring

Novel, helical coil is anchored in the pericardial membrane

Unique, Intrapericardial Placement

Intrapericardial balloon is advanced over the coil anchor wire and secured in place

ECG Synchronization

Balloon inflation is ECG-synchronized to patient’s natural heart rhythm

Continous Monitoring

The system provides continuous monitoring & operation of the device

Highly differentiated technology

This novel implant and its extravascular placement (using a simple, less invasive procedure) is designed to avoid many of the risks and complications of current, temporary MCS devices

Extravascular/extracardiac

Less invasive and avoids hemolysis, stroke

No contrast imaging

Reduces contrast-induced nephropathy

No anticoagulants

Minimizes bleeding

THE OPPORTUNITY

Platform play with multi-billion $ global markets*

$18B

Acute Market | Cardiogenic Shock

$9B

Chronic Market | Heart Failure

Experienced Leadership Team

100+ years of combined experience successfully advancing innovation in leading MedTech companies

Gerardo Noriega

President/CEO

Albert Chin, MD

Chief Innovation Officer

Jim Heslin

IP Counsel

Susan Osborne

VP Regulatory, Clinical and Quality

Bezhad Behrooz

VP R&D and Operations

Ann Benham

Head of Marketing

World-Renowned Clinical Advisory Board

Daniel Burkhoff, MD, Ph.D

Director of Heart Failure,
Hemodynamics & MCS Cardiovascular
Research Foundation

Prof. Petr Neužil, MD

Chairman, Dept of Cardiology, Na
Homolce Hospital, Prague, CZ

Mitchell Krukoff, MD

Director, Cardiovascular Devices Unit, Duke University Medical Center

Kendrick Shunk, MD

Chief Interventional Cardiology UCSF/SFVA

Dan Meyer, MD

Chief of Cardiac Transplantation, Baylor Scott & White Hospital Dallas

William O'Neill, MD

Medical Director of the Center for Structural Heart Disease, Henry Ford Hospital

Henry Hsia, MD

Chief of VT and Electrophysiology at UCSF, FACC, Professor of Medicine

Announcements

PercAssist's PSCA System - Intrapericardial Mechanical Circulatory Support (MCS) System for Cardiogenic Shock Presented at the TCT24

PercAssist, Inc., a medical device company developing innovative technology for extravascular / extracardiac Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced that new data was presented at two sessions at the Transcatheter Cardiovascular Therapeutics (TCT24) Conference in Washington, DC, Oct. 27-30, 2024.

PercAssist Announces Multiple Patients Treated In the EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure

PercAssist, Inc. announces additional successful in human use of its percutaneous subxiphoid cardiac assist (PSCA) device to support an acute myocardial infarction patient with decompensated heart failure at NA Homolce Hospital in Prague with hemodynamic stabilization of the patient for a five day period.

PercAssist Announces First Patient Treated in EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure

PercAssist, Inc. announces the successful first in human use of its percutaneous subxiphoid cardiac assist (PSCA) device to support an acute myocardial infarction patient with decompensated heart failure at NA Homolce Hospital in Prague with hemodynamic stabilization of the patient for a five day period.

Innovative Heart Failure Treatment to be Highlighted at the American College of Cardiology

PercAssist to present cutting-edge heart failure technology at major cardiology annual meeting.

PercAssist one of ten finalists at the ADA 2022 Silicon Valley Leaders Forum HealthTech Showcase

Company's technology showcased at prestigious competition.